NCT06576635 2026-01-20
LUNG-05
University of Illinois at Chicago
Phase NA Recruiting
Clinical Trials
14 trialsNCT06304441 2025-09-29
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
Guangzhou Medical University
Phase NA Recruiting
NCT06649448 2024-10-18
EF-001
Shandong Cancer Hospital and Institute
Phase NA Not yet recruiting
NCT04552613 2024-01-16
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase NA Completed
NCT05527808 2023-06-08
A Single-arm Exploratory Study of Neoadjuvant Therapy
Guangzhou Institute of Respiratory Disease
Phase NA Unknown
NCT05305885 2022-09-30
Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis
The First Hospital of Jilin University
Phase NA Unknown
NCT01063283 2019-11-18
AVF4759
University of Chicago
Phase NA Completed
NCT03671538 2018-09-17
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
The First Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT03489616 2018-04-05
CRAGMOLC
Shandong Cancer Hospital and Institute
Phase NA Unknown
NCT02148380 2016-04-20
Combination of Chemotherapy and Gefitinib as First-line Treatment
Shanghai Chest Hospital
Phase NA Completed
NCT01209520 2015-02-24
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
University of Miami
Phase NA Completed
NCT01860508 2013-07-08
A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers
Fudan University
Phase NA Unknown
NCT01004601 2009-10-30
Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer
Chang Gung Memorial Hospital
Phase NA Completed
NCT00903292 2009-05-18
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
National Cheng-Kung University Hospital
Phase NA Unknown